Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary�Syndrome ODYSSEY OUTCOMES Trial

AllNews Books Images Maps Videos Shopping

Search tools

Past month

All results

All results
Verbatim

Clear

Scholarly articles for Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

scholar.google.com › citations

… acute coronary syndrome: ODYSSEY OUTCOMES trial
Jukema � Cited by 172

Agreement Between Mega-Trials and Smaller Trials - JAMA Network

jamanetwork.com › journals › jamanetworkopen › fullarticle

Sep 6, 2024 � This meta-analysis compares results of mega-trials with results from meta-analyses of smaller trials for the primary outcome and all-cause mortality.

2024 Egyptian consensus statement on the role of non-statin ...

tehj.springeropen.com › articles

Sep 20, 2024 � ... Odyssey Outcomes Trial ... Alirocumab and cardiovascular outcomes after acute coronary syndrome. ... acute coronary syndrome: the IMPROVE-IT trial. J�...

identifying patients at highest risk of recurrent cardiovascular events ...

www.tandfonline.com › ... › List of Issues › Latest Articles

Sep 11, 2024 � The FOURIER trial enrolled a population with stable ASCVD while ODYSSEY-Outcomes enrolled patients with recent ACS, with a median time from index ACS to�...

Dr. C. Michael Gibson, MD | Boston, MA | Cardiologist

health.usnews.com › Doctors

8 days ago � Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. Bram J. Geller�...

[PDF] S3-LEITLINIE ZUR DIAGNOSTIK, THERAPIE UND NACHSORGE ...

Sep 18, 2024 � Alirocumab and Cardiovascular. Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. 197. Sabatine MS, Giugliano RP, Keech AC�...

Images

View all

2024 Egyptian consensus statement on the role of non-statin ...

View all